Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335212 | 1.00 | AR (0.46) | ARSLC22A12POLBGAAEZH2 | |
| SCHEMBL4374421 | 0.83 | AR (0.55) | ARSLC22A12POLBGAAEZH2 | |
| SCHEMBL5143073 | 0.83 | SLC22A12 (0.49) | SLC22A12PGR | |
| SCHEMBL11115045 | 0.83 | GAA (0.53) | ARPOLBGAAPDE4APDE4B | |
| SCHEMBL30372318 | 0.83 | POLB (0.44) | ARSLC22A12POLBGAAEZH2 | |
| SCHEMBL29574172 | 0.83 | TTR (0.56) | ARSLC22A12POLBGAAEZH2 | |
| SCHEMBL5143178 | 0.83 | AR (0.54) | ARPOLBGAAEZH2PGR | |
| SCHEMBL27546530 | 0.81 | SLC22A12 (0.45) | ARSLC22A12POLBGAAEZH2 | |
| SCHEMBL30947422 | 0.79 | POLB (0.48) | POLBGAA | |
| SCHEMBL7054403 | 0.78 | GAA (0.64) | ARSLC22A12POLBGAAPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | TYR, NFE2L2, CYP1A1 | AR 1336/4885SLC22A12 1860/4885POLB 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.